https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2020-07-27 / Ther Apher Dial 2020 Oct;24(5):482-491
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2020-07-27 / Ther Apher Dial 2020 Oct;24(5):482-4912020-07-27 00:00:002021-05-19 14:28:19Immunotherapy employing dendritic cell vaccination for patients with advanced or relapsed esophageal cancer
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2020-07-27 / J. Investig. Med. 2020 Jul;
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2020-07-27 / J. Investig. Med. 2020 Jul;2020-07-27 00:00:002020-07-27 00:00:00Advanced clinical trials of dendritic cell vaccines in ovarian cancer
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2020-07-23 / Adv Biosyst 2020 Jul;:e2000061
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2020-07-23 / Adv Biosyst 2020 Jul;:e20000612020-07-23 00:00:002020-07-23 00:00:00Exosomes in Tumor Immunotherapy: Mediator, Drug Carrier, and Prognostic Biomarker
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2020-07-23 / Biomedicines 2020 Jul;8(8)
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2020-07-23 / Biomedicines 2020 Jul;8(8)2020-07-23 00:00:002021-11-15 19:51:32Evidence-Based Medicine in Oncology: Commercial Versus Patient Benefit
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2020-07-19 / Int J Mol Sci 2020 Jul;21(14)
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2020-07-19 / Int J Mol Sci 2020 Jul;21(14)2020-07-19 00:00:002020-07-19 00:00:00Modulated Electro-Hyperthermia Resolves Radioresistance of Panc1 Pancreas Adenocarcinoma and Promotes DNA Damage and Apoptosis In Vitro
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2020-07-14 / Pharmaceutics 2020 Jul;12(7)
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2020-07-14 / Pharmaceutics 2020 Jul;12(7)2020-07-14 00:00:002020-07-14 00:00:00Harnessing the Complete Repertoire of Conventional Dendritic Cell Functions for Cancer Immunotherapy
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2020-07-13 / Immunol. Invest. 2020 Jul;:1-18
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2020-07-13 / Immunol. Invest. 2020 Jul;:1-182020-07-13 00:00:002020-07-13 00:00:00Intranodal Administration of Neoantigen Peptide-loaded Dendritic Cell Vaccine Elicits Epitope-specific T Cell Responses and Clinical Effects in a Patient with Chemorefractory Ovarian Cancer with Malignant Ascites
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2020-07-07 / Cancers (Basel) 2020 Jul;12(7)
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2020-07-07 / Cancers (Basel) 2020 Jul;12(7)2020-07-07 00:00:002020-07-07 00:00:00Advances in Anti-Cancer Immunotherapy: Car-T Cell, Checkpoint Inhibitors, Dendritic Cell Vaccines, and Oncolytic Viruses, and Emerging Cellular and Molecular Targets
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2020-07-04 / Cancer Immunol. Immunother. 2020 Jul;
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2020-07-04 / Cancer Immunol. Immunother. 2020 Jul;2020-07-04 00:00:002020-07-04 00:00:00Potent anti-myeloma efficacy of dendritic cell therapy in combination with pomalidomide and programmed death-ligand 1 blockade in a preclinical model of multiple myeloma
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2020-07-02 / Signal Transduct Target Ther 2020 Jul;5(1):114
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2020-07-02 / Signal Transduct Target Ther 2020 Jul;5(1):1142020-07-02 00:00:002020-07-02 00:00:00Rewiring local immune milieu by boosting dendritic cell for pancreatic cancer treatment
